Eli Lilly raised its annual revenue forecast October 29 after third-quarter sales increased 39% to $24.4 billion, driven primarily by Mounjaro and Zepbound.
The drugmaker said worldwide volume grew 53%, partly offset by a 15% decline in realized prices. U.S. revenue rose 34% to $15.1 billion; revenue outside the United States increased 47% to $9.3 billion.
The quarter included approximately $900 million in benefits, principally Jardiance milestones and favorable changes to rebate and discount estimates. Those items contributed to the reported growth.
Net income rose to $6.5 billion from $5.6 billion. Reported earnings per share increased to $7.22 from $6.21, while adjusted earnings were $7.48 per share. Both reported and adjusted quarterly earnings included $4.57 per share of acquired in-process research and development charges.
Lilly now forecasts $91 billion–$92 billion in annual revenue, up from $85 billion–$87 billion. However, it lowered its adjusted earnings range to $35–$36 per share from $35.50–$36.50 because the research charges outweighed improvements in its underlying outlook.
These are corporate financial results and management forecasts; they do not establish a medicine’s suitability for an individual patient.
Sources: Eli Lilly — October 29 Financial Results: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full